NCT05193578View on ClinicalTrials.gov

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 18, 2024

Study Completion Date

May 1, 2024

Conditions
SchizophreniaPrediabetic State
Interventions
DRUG

Semaglutide, 1.34 mg/mL

Semaglutide, 1.34 mg/mL

OTHER

Placebo

Semaglutide-Placebo

Trial Locations (1)

Unknown

Odense University Hospital, Odense

All Listed Sponsors
collaborator

Region Zealand

OTHER

collaborator

Region of Southern Denmark

OTHER

collaborator

Steno Diabetes Center Sjaelland

OTHER_GOV

collaborator

Steno Diabetes Center Odense

OTHER

lead

Jan Frystyk

OTHER

NCT05193578 - Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes | Biotech Hunter | Biotech Hunter